VX-993
Phase 2Small molecule
Vertex PharmaceuticalsVX-993 is one of 32 small molecule programs targeting Peripheral Neuropathy. It is currently in Phase 2.
1
Indications
9
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Peripheral Neuropathy
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Savella
AbbVieApproved
Neurontin
VViatris Specialty LLC
Approved
Accupril
PfizerApproved
Velcade
SShilpa Grover, MD, MPH
Approved
Adrucil
EElorac, Inc.
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Cymbalta
Jazz PharmaceuticalsPhase 3
Eloxatin
TevaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Phase 12 trials
Interaction1 trial
Efficacy and Safety1 trial
3 more indications
Drug Interactions1 trial
Peripheral Neuropathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VX-993. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company